Posted by AndrewB on June 24, 2000, at 10:00:22
In reply to Re: Question for Andrew B » Scott, posted by margret on June 24, 2000, at 8:05:34
Scott,
I think my post is quite clear that the use of Naphazoline, an alpha andrenergic agonist, as a diagnostic tool to determine if adrafinil or reboxetine will be effective is something that I have concluded rather than a standard accepted and proven practice. However, if you read literature concerning the treatment of CFIDS patients, it is clear that a variety of alpha 1 agonists/stimulators with short and longer onsets of action may be used with similar results to create arousal. This class of meds works for some but not for other with CFIDs patients. The same can be said for depressed patient with hypoarousal; some but not all will respond positively to alpha 1 agonists/stimulators. The problem with (at least some of) the short onset of action agonists like Naphazoline is that some, an probably most, people quickly develop a tolerance to its effects. The tolerance problem does not negate Naphazoline’s importance as a diagnostic tool. It is the first drug applied by Dr. Goldberg to his CFIDs patients as he tries to profile receptor dysfunction. So again I say, I believe that if you go down to the corner drugstore and get a bottle of Naphazoline eye drops (for getting the red out) and apply them as directed in my first post, you will get a pretty good idea whether you will respond positively to adrafinil or reboxetine.
Magret, the information insert in the box of Vasocon eyedrops, which has Naphazoline as the active ingrediant, include the warnigs that it shouldn't be used if you have glaucoma, high blood pressure or heart irregularites. If you could , Margret, could you let us know which of the warnings you listed apply specifically to Naphazoline.
AndrewB
poster:AndrewB
thread:36854
URL: http://www.dr-bob.org/babble/20000619/msgs/38248.html